| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 2.76 | 76.0% | 26.2% |
| Total Income | 2.76 | 76.0% | 26.2% |
| Expenditure | 95.29 | 0.8% | 25.6% |
| PBT | — | ||
| Net Profit | -82.18 | 7.3% | 31.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.94 | 1.1% | 14.6% |
Kymera Therapeutics Announces Q3 2025 Financial Results
04 May 2026 · 4 May, 8:09 am
Summary
Kymera Therapeutics announced its third quarter 2025 financial results, reporting collaboration revenues of $2.8 million. Research and development expenses increased to $74.1 million, primarily due to investments in the STAT6 program and other discovery programs. The company reported a net loss of $82.2 million for the quarter. As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents, and investments, providing a cash runway into the second half of 2028.
Key Highlights
- 1
Kymera Therapeutics reported $2.8 million in collaboration revenues for the third quarter of 2025.
- 2
Research and development expenses increased to $74.1 million for the third quarter of 2025.
- 3
The company's net loss was $82.2 million for the third quarter of 2025.
- 4
Kymera Therapeutics had $978.7 million in cash, cash equivalents, and investments as of September 30, 2025.
- 5
Enrollment and dosing were completed in the KT-621 BroADen Phase 1b trial in atopic dermatitis patients, with data expected in December 2025.
- 6
The KT-621 BROADEN2 Phase 2b trial in AD has been initiated.
- 7
KT-579 IND-enabling studies are completed, with Phase 1 clinical trial expected to start in early 2026.
Management Comments
Nello Mainolfi
Our team has made impressive research, clinical, and regulatory progress this quarter to advance our first-in-class oral degrader medicines, and we look forward to several important milestones through the fourth quarter and early next year. We’ve completed patient enrollment and dosing in the KT-621 BroADen Phase 1b trial in AD, marking a significant moment in the industry as the first STAT6-directed agent in patients, and we plan to share the full data set next month. Additionally, we’ve initiated the KT-621 BROADEN2 Phase 2b trial in AD and are on track to start BREADTH, the Phase 2b asthma study, in the first quarter of 2026, positioning us on an accelerated development path to multiple registrational studies across areas of significant unmet need. We were pleased to share additional preclinical efficacy data for KT-579 showcasing our novel oral approach to modulating IRF5, a key driver of multiple autoimmune disease pathologies. This program is on track for clinical entry in early 2026. These important milestones across our industry leading oral immunology pipeline underscore our focus on delivering groundbreaking medicines to patients around the world.
Informational and educational content only. Not investment advice.